Humanigen Inc. (HGEN), previously known as KaloBios (KBIO), is a uniquely positioned biopharmaceutical company that is repositioning and developing its proprietary monoclonal antibodies to to meet some critical unmet needs in today’s most advanced cancer science – such as toxicities related to chimeric antigen receptor T-cell (CAR-T) therapy.

 

Interactive Chart